CN1195997A - 流式电穿孔室和方法 - Google Patents
流式电穿孔室和方法 Download PDFInfo
- Publication number
- CN1195997A CN1195997A CN96193177A CN96193177A CN1195997A CN 1195997 A CN1195997 A CN 1195997A CN 96193177 A CN96193177 A CN 96193177A CN 96193177 A CN96193177 A CN 96193177A CN 1195997 A CN1195997 A CN 1195997A
- Authority
- CN
- China
- Prior art keywords
- electrode
- fluid flowing
- flowing passage
- cell
- equipment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004520 electroporation Methods 0.000 title abstract description 164
- 238000000034 method Methods 0.000 title abstract description 106
- 238000001816 cooling Methods 0.000 claims abstract description 67
- 239000012530 fluid Substances 0.000 claims description 45
- 230000000694 effects Effects 0.000 claims description 21
- 230000005684 electric field Effects 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 11
- 238000009434 installation Methods 0.000 claims description 5
- 239000013536 elastomeric material Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000004033 plastic Substances 0.000 claims description 4
- 229920003023 plastic Polymers 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 3
- 230000003139 buffering effect Effects 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 abstract description 167
- 210000004369 blood Anatomy 0.000 abstract description 109
- 239000008280 blood Substances 0.000 abstract description 109
- 229910052760 oxygen Inorganic materials 0.000 abstract description 104
- 239000001301 oxygen Substances 0.000 abstract description 104
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 103
- 108010054147 Hemoglobins Proteins 0.000 abstract description 71
- 102000001554 Hemoglobins Human genes 0.000 abstract description 71
- 239000000203 mixture Substances 0.000 abstract description 31
- 210000002381 plasma Anatomy 0.000 abstract description 26
- 210000001519 tissue Anatomy 0.000 abstract description 24
- 238000000926 separation method Methods 0.000 abstract description 23
- 239000012637 allosteric effector Substances 0.000 abstract description 21
- 238000011282 treatment Methods 0.000 abstract description 16
- 210000000265 leukocyte Anatomy 0.000 abstract description 14
- 239000003146 anticoagulant agent Substances 0.000 abstract description 13
- 229940127219 anticoagulant drug Drugs 0.000 abstract description 13
- 230000000717 retained effect Effects 0.000 abstract description 5
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000701 coagulant Substances 0.000 abstract 1
- 210000004180 plasmocyte Anatomy 0.000 abstract 1
- 238000005215 recombination Methods 0.000 abstract 1
- 230000006798 recombination Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 189
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Diphosphoinositol tetrakisphosphate Chemical compound OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 130
- 239000000243 solution Substances 0.000 description 91
- 238000005406 washing Methods 0.000 description 58
- 239000000725 suspension Substances 0.000 description 47
- 238000003860 storage Methods 0.000 description 40
- 239000007788 liquid Substances 0.000 description 34
- 230000008569 process Effects 0.000 description 32
- 239000012528 membrane Substances 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
- 238000011534 incubation Methods 0.000 description 25
- 230000006872 improvement Effects 0.000 description 24
- 238000011049 filling Methods 0.000 description 21
- 239000000126 substance Substances 0.000 description 20
- 210000000170 cell membrane Anatomy 0.000 description 18
- 210000003027 ear inner Anatomy 0.000 description 15
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 14
- 230000000975 bioactive effect Effects 0.000 description 14
- 239000012535 impurity Substances 0.000 description 14
- 229940068041 phytic acid Drugs 0.000 description 14
- 239000000467 phytic acid Substances 0.000 description 14
- 235000002949 phytic acid Nutrition 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 230000032258 transport Effects 0.000 description 13
- 238000012545 processing Methods 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 239000007853 buffer solution Substances 0.000 description 11
- 238000006213 oxygenation reaction Methods 0.000 description 11
- 230000002685 pulmonary effect Effects 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 238000005336 cracking Methods 0.000 description 9
- 239000007789 gas Substances 0.000 description 9
- 230000008595 infiltration Effects 0.000 description 9
- 238000001764 infiltration Methods 0.000 description 9
- 230000036961 partial effect Effects 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 239000002351 wastewater Substances 0.000 description 8
- 206010019280 Heart failures Diseases 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 230000004087 circulation Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000003792 electrolyte Substances 0.000 description 7
- 238000005538 encapsulation Methods 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 230000003068 static effect Effects 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 208000007502 anemia Diseases 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000005534 hematocrit Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000009413 insulation Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000004417 polycarbonate Substances 0.000 description 6
- 206010007559 Cardiac failure congestive Diseases 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 5
- 229960000367 inositol Drugs 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- -1 nucleotide monophosphate Chemical class 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 229920000515 polycarbonate Polymers 0.000 description 5
- 239000001103 potassium chloride Substances 0.000 description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 5
- 235000011164 potassium chloride Nutrition 0.000 description 5
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000002826 coolant Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000008676 import Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000004065 semiconductor Substances 0.000 description 4
- 229920002379 silicone rubber Polymers 0.000 description 4
- 239000004945 silicone rubber Substances 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 206010022562 Intermittent claudication Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003990 capacitor Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000021156 intermittent vascular claudication Diseases 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- XOHUEYCVLUUEJJ-UHFFFAOYSA-N 2,3-Bisphosphoglyceric acid Chemical compound OP(=O)(O)OC(C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 229920001747 Cellulose diacetate Polymers 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108010064719 Oxyhemoglobins Proteins 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000000110 cooling liquid Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920000447 polyanionic polymer Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 238000012805 post-processing Methods 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000009991 scouring Methods 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- QVHMXAMSRLOKNC-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;7h-purin-6-amine Chemical compound NC1=NC=NC2=C1NC=N2.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O QVHMXAMSRLOKNC-BTVCFUMJSA-N 0.000 description 1
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015287 Erythropenia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000036581 Haemorrhagic anaemia Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 206010021113 Hypothermia Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 229920005479 Lucite® Polymers 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 206010027423 Metabolic alkalosis Diseases 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- QLBOYGFQEQCIFM-UHFFFAOYSA-J S(=O)(=O)([O-])[O-].[Mg+2].P(=O)(O)(O)[O-].[K+].[Cl-].[Na+] Chemical compound S(=O)(=O)([O-])[O-].[Mg+2].P(=O)(O)(O)[O-].[K+].[Cl-].[Na+] QLBOYGFQEQCIFM-UHFFFAOYSA-J 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 239000007994 TES buffer Substances 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JPLSABWRHGMTHM-UHFFFAOYSA-I [Cl-].[Na+].[Cl-].[Mg+2].S(=O)(=O)([O-])[O-].[Mg+2].[Cl-].[Ca+2] Chemical compound [Cl-].[Na+].[Cl-].[Mg+2].S(=O)(=O)([O-])[O-].[Mg+2].[Cl-].[Ca+2] JPLSABWRHGMTHM-UHFFFAOYSA-I 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 208000029039 cyanide poisoning Diseases 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 108010002255 deoxyhemoglobin Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical compound OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229910052571 earthenware Inorganic materials 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000010891 electric arc Methods 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229950000845 politef Drugs 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- NIFIFKQPDTWWGU-UHFFFAOYSA-N pyrite Chemical compound [Fe+2].[S-][S-] NIFIFKQPDTWWGU-UHFFFAOYSA-N 0.000 description 1
- 239000011028 pyrite Substances 0.000 description 1
- 229910052683 pyrite Inorganic materials 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 229910002059 quaternary alloy Inorganic materials 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000287 tissue oxygenation Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000012773 waffles Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3623—Means for actively controlling temperature of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3692—Washing or rinsing blood or blood constituents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
- C12M35/02—Electrical or electromagnetic means, e.g. for electroporation or for cell fusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- G—PHYSICS
- G05—CONTROLLING; REGULATING
- G05D—SYSTEMS FOR CONTROLLING OR REGULATING NON-ELECTRIC VARIABLES
- G05D23/00—Control of temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3616—Batch-type treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0429—Red blood cells; Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3306—Optical measuring means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3379—Masses, volumes, levels of fluids in reservoirs, flow rates
- A61M2205/3382—Upper level detectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/3606—General characteristics of the apparatus related to heating or cooling cooled
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/3673—General characteristics of the apparatus related to heating or cooling thermo-electric, e.g. Peltier effect, thermocouples, semi-conductors
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Anesthesiology (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Sustainable Development (AREA)
- Cell Biology (AREA)
- Electromagnetism (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Automation & Control Theory (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Electrotherapy Devices (AREA)
- External Artificial Organs (AREA)
- Apparatuses And Processes For Manufacturing Resistors (AREA)
- Glass Compositions (AREA)
- Physical Deposition Of Substances That Are Components Of Semiconductor Devices (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/402,145 US5720921A (en) | 1995-03-10 | 1995-03-10 | Flow electroporation chamber and method |
US490695P | 1995-10-06 | 1995-10-06 | |
US60/004,906 | 1995-10-06 | ||
US08/402,145 | 1995-10-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1195997A true CN1195997A (zh) | 1998-10-14 |
Family
ID=26673634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN96193177A Pending CN1195997A (zh) | 1995-03-10 | 1996-03-11 | 流式电穿孔室和方法 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0814855A4 (fr) |
JP (2) | JP3859709B2 (fr) |
KR (1) | KR19980702848A (fr) |
CN (1) | CN1195997A (fr) |
AU (1) | AU5305096A (fr) |
CA (1) | CA2214800C (fr) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6773669B1 (en) | 1995-03-10 | 2004-08-10 | Maxcyte, Inc. | Flow electroporation chamber and method |
US7029916B2 (en) | 2001-02-21 | 2006-04-18 | Maxcyte, Inc. | Apparatus and method for flow electroporation of biological samples |
US7141425B2 (en) | 2001-08-22 | 2006-11-28 | Maxcyte, Inc. | Apparatus and method for electroporation of biological samples |
US7771984B2 (en) | 2004-05-12 | 2010-08-10 | Maxcyte, Inc. | Methods and devices related to a regulated flow electroporation chamber |
CN101857836A (zh) * | 2009-11-10 | 2010-10-13 | 北京大学 | 一种流式电穿孔装置及*** |
CN101928666A (zh) * | 2010-07-30 | 2010-12-29 | 北京大学 | 一种流式电穿孔装置及*** |
CN102665453A (zh) * | 2009-12-23 | 2012-09-12 | 曼海姆/奥克森福特旭德楚克股份公司 | 用于电穿孔的反应器*** |
CN1965079B (zh) * | 2004-06-12 | 2012-12-05 | 英杰生命新加坡私人有限公司 | 具有长中空件的电穿孔装置 |
CN103060191A (zh) * | 2004-06-12 | 2013-04-24 | 英杰生命新加坡私人有限公司 | 一种电穿孔*** |
CN107530486A (zh) * | 2015-05-08 | 2018-01-02 | 生物磁溶液有限公司 | 免疫磁性细胞分离的装置和方法 |
CN107872982A (zh) * | 2015-03-31 | 2018-04-03 | 昂科赛克医疗公司 | 用于改进的基于组织感测的电穿孔的***和方法 |
CN108795750A (zh) * | 2018-05-28 | 2018-11-13 | 深圳先进技术研究院 | 一种带冷却功能的电穿孔装置 |
US11071860B2 (en) | 2019-02-06 | 2021-07-27 | Oncosec Medical Incorporated | Systems and methods for detecting fault conditions in electroporation therapy |
CN113260697A (zh) * | 2018-12-20 | 2021-08-13 | 国立大学法人丰桥技术科学大学 | 电穿孔装置以及外来物质导入细胞的制造方法 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1161270B1 (fr) * | 1999-03-17 | 2007-01-10 | Haemonetics Corporation | Systeme de traitement du sang |
US7601268B2 (en) * | 2003-05-27 | 2009-10-13 | Haemonetics Corporation | Continuous blood filtration and method of use |
KR101084528B1 (ko) * | 2008-04-15 | 2011-11-18 | 인비트로겐 싱가포르 피티이. 엘티디. | 전기천공 장치용 파이펫 팁 |
GB201012521D0 (en) | 2010-07-27 | 2010-09-08 | Univ Strathclyde | Integrated perfusion system |
JP6862178B2 (ja) * | 2013-03-13 | 2021-04-21 | ヌバイラ, インコーポレイテッド | 処置のための流体送達システム及び方法 |
US10316335B2 (en) | 2013-03-15 | 2019-06-11 | Maxcyte, Inc. | Methods and compositions for generating stable transfected cells |
CA2982759A1 (fr) | 2015-04-13 | 2016-10-20 | Maxcyte, Inc. | Procedes et compositions permettant de modifier l'adn genomique |
WO2017176253A1 (fr) * | 2016-04-05 | 2017-10-12 | General Electiric Comapny | Composition de plaquettes activées ayant un taux de facteur de croissance ajustable |
JP7466444B2 (ja) | 2017-05-14 | 2024-04-12 | パラゲート メディカル リミテッド | 埋入可能流体抽出システム |
US10435713B2 (en) * | 2017-09-30 | 2019-10-08 | Inscripta, Inc. | Flow through electroporation instrumentation |
WO2020047504A2 (fr) | 2018-08-31 | 2020-03-05 | The Charles Stark Draper Laboratory, Inc. | Procédé et appareil de transfection à haut rendement et à haute efficacité de cellules |
JP7248721B2 (ja) * | 2021-02-17 | 2023-03-29 | ゼネラル・エレクトリック・カンパニイ | 成長因子レベルを調節可能な活性化血小板組成物 |
WO2022224803A1 (fr) | 2021-04-22 | 2022-10-27 | 富士フイルム株式会社 | Dispositif de perforation électrique, procédé d'introduction de matériau bioactif, procédé de production de biomatériau issu de tissu, et biomatériau issu de tissu |
WO2023223931A1 (fr) * | 2022-05-16 | 2023-11-23 | 富士フイルム株式会社 | Dispositif d'électroporation et procédé d'électroporation |
-
1996
- 1996-03-11 AU AU53050/96A patent/AU5305096A/en not_active Abandoned
- 1996-03-11 CN CN96193177A patent/CN1195997A/zh active Pending
- 1996-03-11 KR KR1019970706255A patent/KR19980702848A/ko not_active Application Discontinuation
- 1996-03-11 CA CA002214800A patent/CA2214800C/fr not_active Expired - Lifetime
- 1996-03-11 EP EP96909619A patent/EP0814855A4/fr not_active Withdrawn
- 1996-03-11 JP JP52774896A patent/JP3859709B2/ja not_active Expired - Lifetime
-
2006
- 2006-07-25 JP JP2006202504A patent/JP4171755B2/ja not_active Expired - Lifetime
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6773669B1 (en) | 1995-03-10 | 2004-08-10 | Maxcyte, Inc. | Flow electroporation chamber and method |
US7029916B2 (en) | 2001-02-21 | 2006-04-18 | Maxcyte, Inc. | Apparatus and method for flow electroporation of biological samples |
US7141425B2 (en) | 2001-08-22 | 2006-11-28 | Maxcyte, Inc. | Apparatus and method for electroporation of biological samples |
US7186559B2 (en) | 2001-08-22 | 2007-03-06 | Maxcyte, Inc. | Apparatus and method for electroporation of biological samples |
US7771984B2 (en) | 2004-05-12 | 2010-08-10 | Maxcyte, Inc. | Methods and devices related to a regulated flow electroporation chamber |
US9546350B2 (en) | 2004-05-12 | 2017-01-17 | Maxcyte, Inc. | Methods and devices related to a regulated flow electroporation chamber |
CN103060191A (zh) * | 2004-06-12 | 2013-04-24 | 英杰生命新加坡私人有限公司 | 一种电穿孔*** |
CN103060191B (zh) * | 2004-06-12 | 2015-03-11 | 英杰生命新加坡私人有限公司 | 一种电穿孔*** |
CN1965079B (zh) * | 2004-06-12 | 2012-12-05 | 英杰生命新加坡私人有限公司 | 具有长中空件的电穿孔装置 |
CN101857836A (zh) * | 2009-11-10 | 2010-10-13 | 北京大学 | 一种流式电穿孔装置及*** |
CN101857836B (zh) * | 2009-11-10 | 2013-06-12 | 昆山文曲生物微***有限公司 | 一种流式电穿孔装置及*** |
CN102665453A (zh) * | 2009-12-23 | 2012-09-12 | 曼海姆/奥克森福特旭德楚克股份公司 | 用于电穿孔的反应器*** |
CN102665453B (zh) * | 2009-12-23 | 2016-02-24 | 曼海姆/奥克森福特旭德楚克股份公司 | 用于电穿孔的反应器*** |
CN101928666B (zh) * | 2010-07-30 | 2013-04-03 | 北京大学 | 一种流式电穿孔装置及*** |
CN101928666A (zh) * | 2010-07-30 | 2010-12-29 | 北京大学 | 一种流式电穿孔装置及*** |
CN107872982A (zh) * | 2015-03-31 | 2018-04-03 | 昂科赛克医疗公司 | 用于改进的基于组织感测的电穿孔的***和方法 |
US11318305B2 (en) | 2015-03-31 | 2022-05-03 | Oncosec Medical Incorporated | Systems and methods for improved tissue-sensing based electroporation |
CN107872982B (zh) * | 2015-03-31 | 2022-10-28 | 昂科赛克医疗公司 | 用于改进的基于组织感测的电穿孔的***和方法 |
CN107530486A (zh) * | 2015-05-08 | 2018-01-02 | 生物磁溶液有限公司 | 免疫磁性细胞分离的装置和方法 |
CN108795750A (zh) * | 2018-05-28 | 2018-11-13 | 深圳先进技术研究院 | 一种带冷却功能的电穿孔装置 |
CN113260697A (zh) * | 2018-12-20 | 2021-08-13 | 国立大学法人丰桥技术科学大学 | 电穿孔装置以及外来物质导入细胞的制造方法 |
US11071860B2 (en) | 2019-02-06 | 2021-07-27 | Oncosec Medical Incorporated | Systems and methods for detecting fault conditions in electroporation therapy |
Also Published As
Publication number | Publication date |
---|---|
CA2214800A1 (fr) | 1996-09-19 |
JP4171755B2 (ja) | 2008-10-29 |
CA2214800C (fr) | 2002-01-22 |
EP0814855A1 (fr) | 1998-01-07 |
EP0814855A4 (fr) | 2002-07-17 |
AU5305096A (en) | 1996-10-02 |
KR19980702848A (ko) | 1998-08-05 |
JP3859709B2 (ja) | 2006-12-20 |
JP2007007430A (ja) | 2007-01-18 |
JPH11502133A (ja) | 1999-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1195997A (zh) | 流式电穿孔室和方法 | |
US5720921A (en) | Flow electroporation chamber and method | |
US6074605A (en) | Flow electroporation chamber and method | |
US6485961B1 (en) | Electrodes having a continuous, crystalline metal nitride coating and method of use | |
US5612207A (en) | Method and apparatus for encapsulation of biologically-active substances in cells | |
US6773669B1 (en) | Flow electroporation chamber and method | |
JP4486157B1 (ja) | 水素含有生体適用液の製造方法及び製造装置 | |
US4652449A (en) | Encapsulating biological active substances into erythrocytes | |
US20010001064A1 (en) | Flow electroporation chamber and methods of use thereof | |
JP2017122118A (ja) | 赤血球の長期保存システムおよび使用方法 | |
CN1494450A (zh) | 用于提供经调节适于病原体灭活处理的血液成分的手动处理***及方法 | |
CN1200742C (zh) | 用于输注用途的***和组合物 | |
CA2855065A1 (fr) | Preservation et stockage electromagnetiques du sang | |
CA2159005C (fr) | Methode et appareillage pour l'encapsulation de substances biologiquement actives dans les cellules | |
AU754218B2 (en) | Flow electroporation chamber and method | |
CA2363548A1 (fr) | Chambre d'electroporation en flux et procede associe | |
CN115029312B (zh) | 一种血小板外泌体的提取方法 | |
JP3682072B2 (ja) | HbCOのHbO2 への変換方法及びその装置 | |
CN1410529A (zh) | 体外重建的人红细胞及其制备和在血液代用品中的应用 | |
WO2006115273A1 (fr) | Procédé servant à traiter un fluide corporel | |
CA1221653A (fr) | Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus | |
Gerner | Novel Hollow Fiber Applications in Medicine and Biotechnology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: DELAMAD CO.,LTD. Free format text: FORMER OWNER: ENTREMED INC. Effective date: 20010802 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20010802 Address after: Maryland USA Applicant after: Delaware, Ahmed Address before: Maryland USA Applicant before: Entremed, Inc. |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1016096 Country of ref document: HK |